About bioAffinity Technologies, Inc.
http://www.bioaffinitytech.combioAffinity Technologies, Inc. operates as a development-stage company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and treatment. The firm develops proprietary in-vitro diagnostic tests and targeted cancer therapeutics using breakthrough technology that preferentially targets cancer cells.
CEO
Maria Zannes
Compensation Summary
(Year 2024)
Salary $291,666
Stock Awards $149,998
Incentive Plan Pay $30,000
All Other Compensation $5,491
Total Compensation $477,155
Industry Medical - Diagnostics & Research
Sector Healthcare
Went public N/A
Method of going public IPO
Full time employees 57
Price Target
Target High $0
Target Low $0
Target Median $0
Target Consensus $0
Market Cap $1.16 M
52w High $0.47
52w Low $0.28
P/E 0
Volume 1
Outstanding Shares 4.50M
About bioAffinity Technologies, Inc.
http://www.bioaffinitytech.combioAffinity Technologies, Inc. operates as a development-stage company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and treatment. The firm develops proprietary in-vitro diagnostic tests and targeted cancer therapeutics using breakthrough technology that preferentially targets cancer cells.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $1.45M ▲ | $2.68M ▼ | $-5.05M ▼ | -349.3% ▼ | $-4.74 ▲ | $-4.93M ▼ |
| Q2-2025 | $1.27M ▼ | $2.77M ▼ | $-4.06M ▼ | -319.88% ▼ | $-5.07 ▼ | $-3.91M ▼ |
| Q1-2025 | $1.85M ▼ | $3.11M ▼ | $-2.66M ▲ | -143.53% ▼ | $-4.8 ▲ | $-2.48M ▲ |
| Q4-2024 | $2.21M ▼ | $3.44M ▲ | $-2.97M ▼ | -134.4% ▼ | $-6.3 ▼ | $-2.79M ▼ |
| Q3-2024 | $2.35M | $2.88M | $-2M | -85.13% | $-4.8 | $-1.83M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $7.67M ▲ | $11.55M ▲ | $2.64M ▼ | $8.9M ▲ |
| Q2-2025 | $802.84K ▲ | $4.75M ▼ | $6.89M ▲ | $-2.14M ▼ |
| Q1-2025 | $444.71K ▼ | $5.55M ▼ | $4.11M ▲ | $1.44M ▼ |
| Q4-2024 | $1.11M ▲ | $6.51M ▼ | $3.91M ▲ | $2.6M ▼ |
| Q3-2024 | $756.58K | $6.55M | $3.43M | $3.12M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-5.05M ▼ | $-2.48M ▲ | $3.65K ▲ | $9.34M ▲ | $6.87M ▲ | $-2.48M ▲ |
| Q2-2025 | $-4.06M ▼ | $-2.65M ▼ | $-13.43K ▲ | $3.02M ▲ | $358.13K ▲ | $-2.66M ▼ |
| Q1-2025 | $-2.66M ▲ | $-1.64M ▲ | $-50.79K ▼ | $1.03M ▼ | $-660.59K ▼ | $-1.69M ▼ |
| Q4-2024 | $-2.97M ▼ | $-1.68M ▲ | $-1 ▲ | $2.03M ▲ | $348.71K ▲ | $-1.68M ▲ |
| Q3-2024 | $-2M | $-1.71M | $-9.41K | $1.67M | $-44.73K | $-1.72M |
Revenue by Products
| Product | Q1-2024 | Q2-2024 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 Health Care Patient Service | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 Other Revenues | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 Health Care Other | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
CEO
Maria Zannes
Compensation Summary
(Year 2024)
Salary $291,666
Stock Awards $149,998
Incentive Plan Pay $30,000
All Other Compensation $5,491
Total Compensation $477,155
Industry Medical - Diagnostics & Research
Sector Healthcare
Went public N/A
Method of going public IPO
Full time employees 57
Price Target
Target High $0
Target Low $0
Target Median $0
Target Consensus $0